𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Indomethacin enhancement of spleen-cell responsiveness to mitogen stimulation in tumorous mice

✍ Scribed by Louis M. Pelus; Helen R. Strausser


Publisher
John Wiley and Sons
Year
1976
Tongue
French
Weight
590 KB
Volume
18
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Spleen cells removed from C57Bl/6J mice bearing a methylcholanthrene‐induced fibrosarcoma (MC‐16) demonstrate suppressed responsiveness to phytohemagglutinin (PHA) and bacterial lipopolysaccharide (LPS) induced mitogenesis as compared to non‐tumorous mice. A similar depression of PHA‐induced mitogenesis was observed with spleen cells from C3H/HeJ mice bearing syngeneic mammary adenocarcinomas (C3HBA). The administration of indomethacin, a non‐competitive irreversible prostaglandin (Pg) synthesis inhibitor, (75 or 100 μg/mouse, IP) on an alternate day basis to groups of tumor‐bearing mice of both strains, significantly enhanced immune cell responsiveness to mitogenic stimulation. The addition of indomethacin (10 μg/ml) to cultures of spleen cells from these tumor‐bearing mice, as well as to DBA/1J mice bearing the Cloudman S‐91 melanoma, enhanced spleen‐cell responsiveness to mitogen‐induced DNA synthesis by as much as 156%. Indomethacin administration in vivo or in vitro had no significant effect on mitogen‐induced DNA synthesis of spleen cells from non‐tumor‐bearing animals. It is hypothesized that tumors, or tumor‐cell antigens, increase Pg production of a population of spleen cells, and that the increased Pg content of the spleen may be important in controlling immune responsiveness in mice.


📜 SIMILAR VOLUMES


Indomethacin-sensitive suppressor cells
✍ Moshe Glaser 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 English ⚖ 770 KB

## Abstract Specific secondary cytotoxic reactivity (as measured by ^51^Cr‐release assay) against SV 40‐induced tumor‐associated antigens was generated __in vitro__ in spleen cells of tumor‐free (BALB/c × C57 BL/6)F~1~ (CBF~1~) mice immunized against a syngeneic SV 40‐induced tumor of BALB/c origin